A phase II study of first-line gefitinib for advanced and recurrent EGFR mutation positive non-small cell lung cancer with high-risk factors.
Phase of Trial: Phase II
Latest Information Update: 12 Jul 2017
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Jul 2017 Status changed from active, no longer recruiting to completed.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 28 May 2015 Status changed from recruiting to active no longer recruiting as reported by University Hospital Medical Information Network - Japan record.